CARL: Falling Wedge detected on 3 Nov 2026

CARL is forming a falling wedge pattern with strong technical structure scoring 15.0/15 on support/resistance definition. The pattern sits near resistance at $14.72 with current price at $15.02. Key support lies at $13.19, providing a 1.83-point cushion (12.2% risk). Volume ratio of 1.26x confirms above-average participation, though volume score of 7.0/12 suggests moderate pressure. Breakout score of 10.83/13 indicates marginal strength. The overall pattern quality scores 64.83/98, with a 68.94% win probability. Technical indicators show neutral momentum—RSI at 53.32 lacks directional bias, MACD histogram positive at 0.1143, and Bollinger position at 0.704 near center.

Carlsmed will report Q3 2026 financial results on November 10, 2026, just 7 days from the pattern detection date, creating near-term earnings volatility. The company has demonstrated strong execution: the company launched the aprevo® Lumbar Bi-lateral Posterior System on October 14, 2026, and appointed Tony Jarc as Chief Product and AI Officer on October 1, 2026, signaling AI-driven product innovation. In Q2 2026, Carlsmed raised full-year guidance, and Q2 revenue reached $18.9 million, up 57% year-over-year. Management strengthening continues: Richard Heppenstall was appointed CFO on September 28, 2026. The health care sector regime is bullish (0.81 score), providing tailwind despite the broader bearish market regime (-0.31). Recent analyst actions show confidence—BTIG raised its price target to $24.

A successful falling wedge breakout from $14.72 resistance would target $15.73 (conservative measure), representing 0.71 points of upside. Based on historical falling wedge performance, the pattern suggests potential for a 4.8% move to target. Volume should confirm above the 20-day average of 74,130 shares, with current volume at 93,747 already demonstrating 26% above-average participation. The setup fails on a close below $13.19 (key support), which would negate the wedge structure and trigger a deeper correction. The 68.94% win probability indicates slightly better-than-coin-flip odds of successful breakout, though this is dampened by modest pattern quality and moderate volume conviction.

Q3 earnings release on November 10, 2026 is imminent—only one week away—creating binary event risk that could gap past pattern targets in either direction. Beta of -0.18 indicates negative correlation to broader market, exposing the setup to adverse market moves given the bearish regime score of -0.31. Elevated volatility at 20-day reading of 0.4567 (5.59% ATR) increases whipsaw risk during breakout attempts. While no analyst downgrades are evident, Carlsmed filed a patent infringement lawsuit against DeGen Medical, creating legal uncertainty. The stock trades 12.83% below its 52-week high, suggesting recent momentum loss. Volume score of 7.0/12 remains modest—not high enough to eliminate false breakout risk. Negative equity dilution signals through inducement grants and RSU awards reduce buyback-driven support.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.